Exploiting novel cell cycle targets in the development of anticancer agents.
In this review we provide a brief background on the cell cycle and then focus on two novel and emerging areas of cell cycle research that may prove to have significant relevance to the development of novel anticancer agents. In particular, we review the emerging evidence to suggest that histone deacetylase inhibitors may possess cancer cell-specific cytotoxicity due to their ability to target a novel G2/M checkpoint. We also review the recent literature supporting the proposition that inhibition of E2F activity in epithelial cancer cells may prove to be a useful differentiation therapy that operates via cell cycle-dependent and cell cycle-independent mechanisms.
Wong
Chung Fai
CF
Cancer Biology Programme, Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Queensland, Australia.
Guminski
Alexander
A
Saunders
Nicholas A
NA
Burgess
Andrew J
AJ
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002453:Cell Cycle / Q000187:drug effects* / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends
D000970:Antineoplastic Agents